

(51) International Patent Classification:
C12Q 1/68 (2006.01)

(21) International Application Number:

PCT/GB2014/052994

(22) International Filing Date:

3 October 2014 (03.10.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1317622.7 4 October 2013 (04.10.2013) GB

(71) Applicants: **F-STAR BIOTECHNOLOGY LTD** [GB/GB]; Moneta B280, Babraham Research Campus, Cambridge Cambridgeshire CB22 3AT (GB). **F-STAR BIOTECHNOLOGISCHE FORSCHUNGS- UND ENTWICKLUNGSGES.M.B.H.** [AT/AT]; Schwarzenbergplatz 7, A-1030 Vienna (AT).(72) Inventors: **LEUNG, Kinmei**; F-star Biotechnology Ltd, Moneta B280, Babraham Research Campus, Cambridge Cambridgeshire CB22 3AT (GB). **SUN, Haijun**; F-star Biotechnology Ltd, Moneta B280, Babraham Research Campus, Cambridge Cambridgeshire CB22 3AT (GB).**BATEY, Sarah**; F-star Biotechnology Ltd, Moneta B280, Babraham Research Campus, Cambridge Cambridgeshire CB22 3AT (GB). **ROWLAND, Robert**; Ely (GB).(74) Agents: **KEIRSTEAD, Tanis** et al.; Mewburn Ellis LLP, 33 Gutter Lane, London, Greater London EC2V 8AS (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

[Continued on next page]

(54) Title: CANCER BIOMARKERS AND USES THEREOF




Figure 6

(57) Abstract: The invention relates the use of Human Epidermal Growth Factor Receptor 2 (HER2) gene copy number and HER2 mRNA levels as biomarkers to identify cancers which will respond to treatment with a specific binding member comprising a HER2 antigen binding site engineered into a structural loop region of a constant domain, e.g. CH3 domain, of the specific binding member, and specific binding members which compete with such a binding member for binding to HER2.



SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*